Summary & Overview
HCPCS J1299: Eculizumab Injection, 2 mg
HCPCS Level II code J1299 represents a 2 mg unit of eculizumab, a high-cost injectable biologic used in several rare, immune-mediated conditions. Nationally, accurate coding for biologic agents like eculizumab matters for patient access, utilization tracking, and payer coverage determinations because dosing and administration can drive significant cost and clinical-management decisions. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. This publication provides a concise briefing on clinical context, typical sites of service, and the billing constructs relevant to J1299. Readers will find an overview of where J1299 is used clinically, common billing considerations, and the types of benchmarks and policy updates that influence coverage and claim adjudication for injectable biologics. The piece highlights how unit-based HCPCS coding for eculizumab interfaces with infusion services and outpatient settings, and it identifies areas where payers commonly apply utilization management or prior authorization (policy specifics vary by payer). Data not provided in the source are noted as unavailable; this summary focuses on national-level implications rather than jurisdictional policy detail.
Billing Code Overview
HCPCS Level II code J1299 describes an injection of eculizumab, 2 mg. This code represents a parenteral biologic therapy administered by intravenous or subcutaneous injection depending on clinical protocol. The service type is injectable biologic medication administration. The typical site of service for delivery of this product is hospital outpatient infusion center, outpatient clinic, or physician office.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient with a confirmed diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) presents for maintenance intravenous therapy with eculizumab. The patient arrives at an outpatient infusion center accompanied by nursing staff, who verify vaccinations (meningococcal), review recent labs (CBC, LDH, renal function), assess vital signs and central or peripheral IV access, and screen for intercurrent infection. The infusion pharmacist prepares eculizumab in a controlled sterile environment, calculating dose based on the ordered milligram amount; billing for the drug is reported in 2 mg units using J1299. During administration, nursing monitors for infusion reactions and documents start/stop times, lot numbers, and any premedication. Post-infusion observation is performed per facility protocol. Typical sites of service are hospital outpatient infusion centers and freestanding ambulatory infusion clinics. Common clinical workflow steps: order verification and dose calculation, vaccine and antibiotic prophylaxis confirmation, preparation and dispensing by pharmacy, IV administration by infusion nursing, monitoring and documentation, and billing using the appropriate HCPCS code J1299 with applicable modifier when indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When partial vials are opened and residual single-use drug is discarded per facility policy |
JZ | No drug administered | When zero drug was administered despite preparation (rare) |
QX | Attending practitioner/CRNA split/shared service | When applicable split/shared rules apply (facility-specific) |
QY | Attending practitioner/physician service furnished by a PA/NP/clinical nurse specialist | When a physician assistant or nurse practitioner furnished the supervising physician’s service |
62 | Two surgeons | When two qualified providers perform distinct parts of a complex procedure (rare for infusion) |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period | If patient requires an urgent related procedure after infusion in an operative setting |
80 | Assistant surgeon | When an assistant surgeon is documented and allowed by payer (rare for infusion) |
82 | Assistant surgeon (when a qualified resident surgeon is not available) | Similar use as 80 when applicable |
59 | Distinct procedural service | When another distinct service/procedure is performed on the same day (Use only if clinically appropriate) |
52 | Reduced services | When the service is partially reduced or not completed as originally described |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208800000X | Hematology & Oncology | Hematologists/oncologists commonly prescribe eculizumab for PNH and related indications |
207RH0000X | Pediatric Hematology-Oncology | Pediatric hematologists manage pediatric patients receiving eculizumab |
363LM0800X | Infusion Therapy | Infusion specialists and registered nurses administer and monitor IV biologics |
207L00000X | Internal Medicine | Hospitalists and internists may manage inpatient infusion and oversight |
3336C0003X | Pharmacy | Clinical pharmacists prepare, verify dosing, and dispense eculizumab |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
D59.5 | Paroxysmal nocturnal hemoglobinuria (PNH) | Primary FDA-approved indication for eculizumab to reduce hemolysis and thrombosis risk |
D61.09 | Other aplastic anemias | Eculizumab may be considered in specific complement-mediated hematologic conditions |
D59.0 | Drug-induced immune hemolytic anemia | Differential diagnosis where complement inhibition may be relevant in select cases |
I82.9 | Phlebitis and thrombosis of unspecified vein | Thrombotic complications in PNH patients treated or monitored during eculizumab therapy |
D57.819 | Other sickle-cell disorders with crisis | In select complex hemolytic disorders, complement inhibitors are considered in investigational or specialty use |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96365 | Intravenous infusion, initial, up to 1 hour | Used for the initial infusion session when eculizumab administration time fits the definition of an initial infusion |
96366 | Intravenous infusion, each additional hour | Billed when infusion duration exceeds the initial hour and additional hours are documented |
96372 | Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular) | Occasionally used for subcutaneous injections of supportive medications (e.g., premedication) if applicable |
36415 | Collection of venous blood by venipuncture | Performed for laboratory monitoring before or after infusion (CBC, LDH, renal function) |
96379 | Unlisted therapeutic, prophylactic, or diagnostic injection/infusion procedure (specify) | Used when a specific infusion scenario is not described by standard infusion codes and payer requires an unlisted code |